Oxana Beskrovnaya, the Chief Scientific Officer of $DYN ($DYN), sold 2,334 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?
The Chart of the Day belongs to the biotechnology company Dyne Therapeutics (DYN) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...
Insiders sold more than 15,000 shares of company stock on Tuesday.
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 ...
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass.,...
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical...